Radiation therapy used most often for prostate cancer regardless of decision-making factors
the ONA take:
The most common treatment for prostate cancer is radiation therapy, regardless of cancer stage, prostate-specific antigen (PSA) level, and prognosis and risk rating.
In an analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for 37,621 men with a prostate cancer diagnosis from 2004 to 2007, the researchers found radiation therapy was the most common treatment, followed by radical prostatectomy and other treatments including watchful waiting or active surveillance (WW-AS).
Radiation treatment was the most common regardless of stage, PSA level, and prognosis and tumor rating; however, PSA level influenced the choice of radical prostatectomy.
Clinical stage, as well as prognosis and tumor rating, influenced patients to choose WW-AS, but cancer stage, PSA level, and prognosis and risk rating prompted a decision to undergo androgen-deprivation therapy (ADT).
The authors reported that increased use of treatments in men with prostate cancer and underuse of active surveillance in men with low-risk disease remain.
Their study concludes that further research into what drives treatment choices among both patients and their physicians are needed.
Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|